文献速递神经肿瘤

卡铂联合长春花碱治疗儿童低级别胶质瘤的回顾性分析

Retrospective analysis of combination carboplatin and vinblastine for pediatric low-grade glioma.
PubMed 文献 · J Neurooncol · 2020-06-06

结论认为C/VBL的EFS与其他单药或联合细胞毒性化疗方案相似。

要点

  • C/VBL方案在初治儿童LGG中1年EFS为69.6%,3年为39.4%,5年为34.5%。
  • 仅2例因治疗相关毒性(卡铂过敏、长春花碱神经病变)永久停药。
  • 9例因发热性中性粒细胞减少住院,7例因中性粒细胞减少延迟化疗一次。

核心结论

  • C/VBL方案治疗儿童LGG的EFS与其他单药或联合细胞毒性化疗方案相似,且毒性可控。

主要发现

  • 1年、3年、5年EFS分别为69.6%、39.4%、34.5%。
  • 9例因发热性中性粒细胞减少住院,7例因中性粒细胞减少延迟化疗一次,2例因毒性永久停药(卡铂过敏1例,长春花碱神经病变1例)。

临床怎么用

  • 对于无法全切的儿童LGG,C/VBL可作为化疗选择之一,需监测中性粒细胞减少及过敏、神经毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Low-grade glioma (LGG) represent the most common pediatric central nervous system tumor. When total surgical resection is not feasible, chemotherapy is first-line therapy in children. Multiple pediatric LGG chemotherapy regimens have been investigated with variable 2-year event free survival (EFS) rates of 39-69%. To date, treatment of pediatric LGG with a carboplatin and vinblastine (C/VBL) chemotherapy regimen has only been evaluated in a phase 1 dose-finding study. METHODS: A retrospective review of pediatric patients with LGG who were treated with C/VBL at Children's Hospital of Colorado or Akron Children's Hospital from 2011 to 2017 was conducted. Data collected included patient demographics, tumor location, disease response, neurofibromatosis 1 (NF1) status, therapy duration and toxicities. Response to therapy was determined by objective findings on imaging and treating physicians' evaluation. RESULTS: Forty-six patients were identified for analysis, all of whom were chemotherapy-naive. Only five patients treated in this cohort had NF1. BRAF fusion was identified in 65% (22/34) of tested tumors. Best therapy response was partial response in nine patients and stable disease in twenty-five patients. Twelve patients had progressive disease. One-year, 3-year, and 5-year EFS probabilities for all patients were 69.6%, 39.4%, and 34.5%, respectively. Nine patients had admissions for febrile neutropenia and seven patients experienced one delay in chemotherapy due to neutropenia. Only two patients had to discontinue this chemotherapy regimen because of treatment-related toxicities [carboplatin allergy (n = 1) and vinblastine neuropathy (n = 1)]. CONCLUSION: C/VBL achieves similar EFS rates to other single-agent and combination cytotoxic chemotherapy regimens for pediatric LGG with manageable toxicities.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nellan A, Wright E, Campbell K, et al. Retrospective analysis of combination carboplatin and vinblastine for pediatric low-grade glioma. J Neurooncol. 2020. PMID: 32506370. doi:10.1007/s11060-020-03549-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。